Entamoeba histolytica infects approximately 10% of the world population, causing up to 50 million cases of invasive amebiasis and 100,000 deaths per year (18) . E. histolytica can cause asymptomatic intestinal infection, acute amebic dysentery, chronic localized intestinal amebiasis, chronic nondysenteric colitis (mimicking inflammatory bowel disease), and amebic liver abscess (13). Groups at high risk of infection in the United States include travelers to areas of endemic infection, sexually active male homosexuals (9) , individuals with acquired immune deficiency syndrome (16) , institutionalized mentally retarded patients (17) (18) (19) , and emigrants from areas of endemic infection such as Mexico (13). Therapy of invasive amebiasis presently requires use of a luminal agent, such as diloxanide furoate, diiodohydroxyquin, or paromomycin, in combination with a tissue-active agent, such as the nitroimidazoles metronidazole and tinidazole or the more toxic emetine derivatives, including dehydroemetine (10) . Erythromycin and tetracycline, reported to be effective in treatment of amebic colitis, are not recommended for eradication of parasites in the intestinal lumen or the liver (1). Availability of a single agent efficacious against all forms of amebiasis and with low levels of toxicity would be a major therapeutic advance, especially if the drug was safe to use during pregnancy.
Azithromycin (CP-62,993) and its analog CP-63,956 are new macrolide antibiotics which differ in structure from erythromycin by a methyl-substituted nitrogen in the macrolide ring (14) . Compared with erythromycin, azithromycin has greater stability at low pH, a prolonged elimination half-life of up to 21.0 h, and up to 10-fold-enhanced tissue penetration in studies of experimental animals (5, 14) . Azithromycin successfully treated experimental anaerobic bacterial liver abscess in mice (5 When a smaller parasite inoculum (6 x 103) and longer incubation period (48 h) were used, growth to a mean of 6.7 x 104 amebae was observed; therefore, complete inhibition of growth occurred at 9% of the control value. Azithromycin and CP-63,956 demonstrated significant inhibitory effects over 48 h at .20 jig/ml, with complete inhibition of growth at .40 ,ug/ml (Table 1 ). The inhibitory activity of erythromycin was observed at concentrations identical to that of azithromycin (Table 1) . Metronidazole was completely inhibitory at .10 ,ug/ml, demonstrating antiamebic activity at lower concentrations compared with those used in the first set of experiments, which used a larger parasite inoculum and shorter (18-h) incubation period (Table 1 ).
These studies demonstrate that azithromycin and CP-63,956 have an in vitro activity against E. histolytica trophozoites equal to those of erythromycin and, at 18 h, metronidazole. Complete inhibition of parasite growth was observed at .40 ,ug of azithromycin per ml, and at least a 90% amebicidal effect was present at 100 ,ug/ml. After a 50-mg/kg (body weight) oral dose, azithromycin reached sustained peak concentrations of >70 ,ug/g in rat liver compared with <10 ,ug/g for erythromycin (5) , indicating a potential clinical relevance for the static and amebicidal activities of azithromycin.
In comparison to our findings, Cedeno and Krogstad (2) reported that the 50% growth inhibitory concentration of erythromycin was 24 pig/ml for E. histolytica HK9. They found that metronidazole at 1.0 ,ug/ml provided complete inhibition of amebic growth at 48 h of incubation (2) . Eubank and Reeves (4) observed with strain H200:NIH a static effect for metronidazole at 1.7 ,ug/ml. We utilized strain HM1: IMSS, which is among the most virulent available in axenic culture. Instead of the radiometric method of Cedeno and Krogstad (2), we preferred to use direct quantitative observations with trypan blue exclusion criteria to determine parasite viability.
Therapy of amebiasis remains problematic; metronidazole is effective in all tissues but requires at least 10 days at high dosage to eradicate luminal amebae (6, 12, 18) . Metronidazole also has substantial gastrointestinal side effects and raises concerns about carcinogenesis and teratogenesis (reviewed in references 7 and 11). Single-dose regimens for treatment of amebiasis with metronidazole or tinidazole have been reported (8, 15) , but these regimens are not without drawbacks or toxicity. The extended half-life of azithromycin, the high concentrations which the drug reaches in tissues such as liver, its stability in stomach acid, its high fecal concentrations, and the low level of clinical toxicity observed with other macrolides such as erythromycin suggest that azithromycin may be useful as a single agent for therapy of amebiasis. The in vitro results reported here indicate a need for the study of azithromycin with animal models of invasive amebiasis and luminal intestinal infection, which would further evaluate the potential of azithromycin treatment of human amebiasis.
This work was supported by a grant from Pfizer Inc.
